InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| Blasticidin | FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatoce... | 2022 | PNAS | Tao Z. et al. | DOI: 10.1073/pnas.2208844119 |
| Puromycin | FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatoce... | 2022 | PNAS | Tao Z. et al. | DOI: 10.1073/pnas.2208844119 |
| Hygromycin B Gold | Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main P... | 2022 | J Med Chem. | Cooper M.S. et al. | DOI: 10.1021/acs.jmedchem.2c01131 |
| Blasticidin | Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main P... | 2022 | J Med Chem. | Cooper M.S. et al. | DOI: 10.1021/acs.jmedchem.2c01131 |
| A549-Dual™ Cells for SARS-CoV-2 studies | Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main P... | 2022 | J Med Chem. | Cooper M.S. et al. | DOI: 10.1021/acs.jmedchem.2c01131 |
| Puromycin | Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main P... | 2022 | J Med Chem. | Cooper M.S. et al. | DOI: 10.1021/acs.jmedchem.2c01131 |
| Zeocin® | Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main P... | 2022 | J Med Chem. | Cooper M.S. et al. | DOI: 10.1021/acs.jmedchem.2c01131 |
| Primocin® | Formulation of Lipid-Free Polymeric Mesoscale Nanoparticles Encapsulating mRNA. | 2022 | Pharm Res. | Skelton R. et al. | DOI: 10.1007/s11095-022-03398-5 |
| IFN-α/β Reporter HEK 293 Cells | Preventing SARS-CoV-2 Infection Using Anti-spike Nanobody-IFN-β Conjugated Ex... | 2022 | Pharm Res. | Lyu X. et al. | DOI: 10.1007/s11095-022-03400-0 |
| Puromycin | CD9, a key actor in the dissemination of lymphoblastic leukemia, modulating C... | 2022 | Blood | Arnaud M.P. et al. | DOI: 10.1182/blood-2015-02-628560 |
| R848 (Resiquimod) | Honeysuckle ( Lonicera japonica) and Huangqi ( Astragalus membranaceus) Suppr... | 2022 | Front Pharmacol. | Yeh Y.C. et al. | DOI: 10.3389/fphar.2021.765553 |
| Normocin™ - Antimicrobial Reagent | Small Molecules as Toll-like Receptor 4 Modulators Drug and In-House Computat... | 2022 | Biomedicines | Pérez-Regidor L. et al. | DOI: 10.3390/biomedicines10092326 |
| HEK-Blue™ hTLR4 | Small Molecules as Toll-like Receptor 4 Modulators Drug and In-House Computat... | 2022 | Biomedicines | Pérez-Regidor L. et al. | DOI: 10.3390/biomedicines10092326 |
| HEK-Blue™ Null2 Cells | Small Molecules as Toll-like Receptor 4 Modulators Drug and In-House Computat... | 2022 | Biomedicines | Pérez-Regidor L. et al. | DOI: 10.3390/biomedicines10092326 |
| Poly(I:C) (HMW) VacciGrade™ | Antibody targeting of E3 ubiquitin ligases for receptor degradation. | 2022 | Nature | Marei H. et al. | DOI: 10.1038/s41586-022-05235-6 |
| R848 VacciGrade™ | Antibody targeting of E3 ubiquitin ligases for receptor degradation. | 2022 | Nature | Marei H. et al. | DOI: 10.1038/s41586-022-05235-6 |
| Alhydrogel® adjuvant 2% | Vivaxin genes encode highly immunogenic, non-variant antigens on the Trypanos... | 2022 | PLoS Negl Trop Dis. | Romero-Ramirez A. et al. | DOI: 10.1371/journal.pntd.0010791 |
| Quil-A® adjuvant | Vivaxin genes encode highly immunogenic, non-variant antigens on the Trypanos... | 2022 | PLoS Negl Trop Dis. | Romero-Ramirez A. et al. | DOI: 10.1371/journal.pntd.0010791 |
| CR3022-derived Anti-SARS-CoV2 RBD mAbs, human & mouse isotypes | Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune resp... | 2022 | NPJ Vaccines | Yankowski C. et al. | DOI: 10.1038/s41541-022-00532-7 |
| Adju-Phos® adjuvant | Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune resp... | 2022 | NPJ Vaccines | Yankowski C. et al. | DOI: 10.1038/s41541-022-00532-7 |